XVIVO's 32% Growth Arrives With a Receipt Attached

XVIVO Perfusion printed SEK 253 million of net sales in Q3 2026, 32% organic growth, a 21% EBITDA margin and SEK 313 million of cash. On the surface it is the fourth consecutive clean quarter, and management's framing — "in line with the first half of the year" — invites you to extrapolate. The interesting part of the call is what sits underneath that number, because a meaningful slice of it does not repeat.

The Quality of 32%

CFO Kristoffer Nordström was unusually explicit: thoracic, the largest business area at SEK 177 million and 51% organic growth, "benefited from approximately SEK 19 million of tailwinds towards the end of the quarter." Of that, SEK 8.5 million was an IFRS reclassification — three OPO device placements that should have been booked as financial leases on day one but were instead caught up retrospectively — and roughly SEK 10 million was inventory built by the largest U.S. customer, an order that landed on the last day of the quarter. Nineteen million on a 253 million base is not a rounding error.

The company also declined to defend its gross margin. Group gross margin fell to 70% from 75%, services went to negative 19% from positive 37%, and thoracic dropped to 80% from 89% — a level Nordström said would be 85% excluding the mix and write-downs, "another level we recognize from earlier quarters." The one genuinely clean line is the product gross margin ex-services at 75%, flat year to date. That is the number to hold onto, because everything else in the P&L this quarter moved for reasons that will not recur in the same direction.

Services remains the open wound: SEK 14 million of sales, down 28%, a business deliberately restructured and staffed ahead of the U.S. heart launch. Asked directly whether XVIVO would keep an in-house organ recovery capability, CEO Christoffer Rosenblad gave a non-answer — "we are continuously evaluating our strategy and go-to-market strategy for all our products" — before Nordström conceded the contracting is slower than hoped: "I just wish it went faster." Management does now guide to services growth in 2027, which is a stronger statement than anything offered in the prior four calls.

The Customer That Decides

The elephant was addressed, but only partly. Nordström put a hard number on it: the largest customer "totaled SEK 132.6 million in 2025" — a figure equivalent to more than half of this quarter's entire group revenue — and that customer is building its own EVLP platform for 2027. On the prior call Rosenblad had already warned the obvious: "The sales value will of course be smaller compared to today." This quarter the honesty went a step further:

But you have a point that there is an end customer who has a say in this one, and it's very clear that the end customer decides.

Management's offset is the OPO hub model, now live with three programs and five more identified in the pipeline, plus new-center growth. "We do see fast growth in our new customers, and we do believe that that will hopefully cover any shortfall," Rosenblad said, immediately qualifying that a "more detailed answer" is owed. Note the phrase “hopefully cover” — Christoffer Rosenblad, CEO · 2026-10-22 — that is a hope, not a plan with numbers attached. Meanwhile the company has started talking openly about competitive dynamics, a topic that has climbed into its top-30 keyword set for the first time; the answer, at least so far, is that a second approved EVLP device has not visibly changed the field, and that going from 20% lung utilization to 50% is a large enough pie to absorb more players.

Three Launches, Three Clocks

The strategic story has rotated decisively from capability-building to commercialization. Heart Assist Transport now tops the company's keyword table, with Heart launch third — a shift from the July call where the language was still about commercial capability and rebuilding sales force.

The CE mark is in hand, and the launch architecture is unusually concrete: a first phase of eight centers running under derogation, then a Tier 2 phase targeting 33 centers in four priority markets with reimbursement established, together representing nearly 40% of European heart transplant clinics. Onboarding starts in December. Q3 heart revenue was a modest SEK 22 million — SEK 9 million Australia/New Zealand, SEK 11 million Europe, SEK 1 million from the U.S. CAP. The clinical hook remains the 76% reduction in severe PDD, which the company repeatedly ties to six additional survivors per hundred patients at one year.

Two dates moved into focus. U.S. heart: the PMA was accepted by the FDA in September, the continued access protocol was extended for another 60 patients, and commercial launch is targeted for late 2027. U.S. liver: a 510(k) submission in H1 2027 with launch in early 2028 — a pathway that only became nameable after the Q-Sub dialogue. Rosenblad was careful that the burden here is usability validation, not a new clinical trial, and that the HOPE/DHOPE label distinction is a deliberate trade: "time to market is prioritized." The caveat is that XVIVO has learned this lesson before — “launching a product without U.S. data will not make it fly” — Christoffer Rosenblad, CEO · 2026-04-24 was the April framing on kidney, and the U.S. liver field already has warm and cold perfusion incumbents with fresh capital.

And then there is the admission that matters more than any launch date. Kidney grew 19% and should grow around 30% next year — but not more, because of a component shortage:

But due to some component changes where there are a shortage situation, we need to allocate them wisely and we will not be able to fulfill the full demand of the market next year in kidney.

That is a self-inflicted ceiling on the fastest-growing abdominal franchise, plus the ongoing manufacturing transfer that clipped liver to 9% growth. Neither is demand-side.

An Island, With the Usual Costs

The global tape offers no cover story here. The market's curated keyword tape for the last twelve quarters is saturated with AI data center demand, memory pricing, tariff refunds and biotech clinical readouts; not one of the hundred-plus companies that reported in the last five days touched organ perfusion or transplant logistics. XVIVO is not riding a wave — it is the wave, entirely on its own execution, which is why a single customer's in-sourcing decision and a component shortage can move the story more than any macro variable.

Management did pre-announce the cost of the next phase: a "slight margin dip during the second half of the year" as the U.S. sales force is staffed ahead of heart and liver approvals. That is consistent with the January doctrine that "growth is more important than profitability," and with a CEO who has spent four years arguing the platform is now built. The question for the next four quarters is narrower and less flattering than the 32% headline: how much of the lung franchise's SEK 133 million anchor customer can the OPO model replace before 2027, and how much of the current margin can survive the sales force that has to be hired before the approvals that justify it.